Named as Takeda’s Chief Integration & Divestiture Management Officer in January 2019, Helen Giza is responsible for overseeing the proposed integration of Takeda and Shire. In this capacity, Giza set up an integration team to develop a comprehensive plan to combine the two companies following closing. The plan will ensure the post-closing combination happens at pace, and in a thoughtful, decisive and thorough manner, subject to engagement with relevant stakeholders, including employee representative bodies, where required.
Ms. Giza has more than 25 years of diverse finance experience, serving and overseeing markets in the U.S., Asia, LATAM and Europe. She has a proven track record of delivering strong performance and profitability improvement while maintaining financial compliance and company values. Experienced in leading strategy, pricing & contracting, accounting and controllership and business development including transactions, integrations and divestments, she is a strategic, innovative thinker who challenges the status quo and is adept at engaging peers and bringing the organization along during times of change.
Previously, Ms. Giza served as Senior Vice President, CFO of the U.S. Business Unit for Takeda Pharmaceuticals, U.S.A, Inc. In that executive leadership role, Ms. Giza was responsible for the overall financial management and strategy of the company. Her financial responsibilities included financial planning, accounting and reporting, finance operations, and her commercial responsibilities included contracts & pricing, commercial planning and forecasting. Ms. Giza had financial responsibility for all U.S. financial entities as well as the U.S. Shared Service Center and maintaining reporting relationships in the U.S. and Japan. Ms. Giza has been involved in Takeda’s transformation efforts serving as Executive sponsor of US BPR implementation & Takeda Business Services initiative and was actively involved in Global Opex program.
Previously, Ms. Giza was the Vice President of Finance and Controller at TAP Pharmaceutical Products Inc., a former joint venture between Takeda and Abbott. She was responsible for financial planning and analysis, financial reporting, business development and licensing financial support, treasury operations and purchasing. Giza was key in the deal design and execution between Takeda and Abbott when the joint venture was dissolved in 2008 and its subsequent integration into Takeda.
Prior to joining TAP, Ms. Giza spent eight years in the automotive supply industry in the U.K., holding a variety of finance leadership positions in large multinational companies. She joined Abbott U.K. in 1999 as plant controller. Ms. Giza moved to Chicago in 2001, where she held finance roles in Abbott’s international division, supporting various manufacturing, distribution and commercial operations in the U.S., Latin America, Pacific Asia, Africa and Japan.
Ms. Giza brings a diverse background having worked in different industries and different countries. She is experienced in navigating global organizations, and interacting with people from diverse cultures across the world.
Ms. Giza is a U.K. Chartered Certified Accountant and received her Master of Business Administration from the Kellogg School of Management at Northwestern University.